GSK To Double Avandia Sales Organization To 3,600 Reps
This article was originally published in Pharmaceutical Approvals Monthly
Following positive results of its ADOPT study, GlaxoSmithKline is redoubling its marketing support for the insulin sensitizer Avandia
You may also be interested in...
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011
The paradoxical finding that Dendreon's cancer immunotherapeutic Provenge (sipuleucel-T) improved overall survival in men with metastatic castration-resistant prostate cancer but did not appear to slow the progression of the disease is raising questions about the future of clinical development for the burgeoning class